Manuel Narvaez
Overview
Explore the profile of Manuel Narvaez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
929
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Navas A, Janko M, Benitez F, Narvaez M, Vasco L, Kansara P, et al.
PLOS Clim
. 2024 Jul;
3(4).
PMID: 39027120
Malaria transmission is influenced by climate and land use/land cover change (LULC). This study examines the impact of climate and LULC on malaria risk in the Ecuadorian Amazon. Weekly malaria...
2.
Arrabal-Gomez C, Beltran-Casanueva R, Hernandez-Garcia A, Bayolo-Guanche J, Barbancho-Fernandez M, Serrano-Castro P, et al.
Cells
. 2024 Apr;
13(8.
PMID: 38667284
This study investigates the combined effects of the neuropeptide Y Y1 receptor (NPY1R) agonist [Leu31-Pro34]NPY at a dose of 132 µg and Ketamine at 10 mg/Kg on cognitive functions and...
3.
Arrabal-Gomez C, Serrano-Castro P, Sanchez-Perez J, Garcia-Casares N, Fuxe K, Borroto-Escuela D, et al.
Expert Opin Ther Targets
. 2024 Apr;
28(4):309-322.
PMID: 38626283
Background: Major Depressive Disorder (MDD) poses a significant challenge to global health, with current treatments often limited by efficacy and onset delays. This study explores the synergistic antidepressant-like effects of...
4.
Borroto-Escuela D, Serrano-Castro P, Sanchez-Perez J, Barbancho-Fernandez M, Fuxe K, Narvaez M
Expert Opin Ther Targets
. 2024 Apr;
28(4):295-308.
PMID: 38622072
Background: Major Depressive Disorder (MDD) is a prevalent and debilitating condition, necessitating novel therapeutic strategies due to the limited efficacy and adverse effects of current treatments. We explored how galanin...
5.
Beltran-Casanueva R, Hernandez-Garcia A, Serrano-Castro P, Sanchez-Perez J, Barbancho-Fernandez M, Garcia-Casares N, et al.
FASEB J
. 2024 Apr;
38(7):e23595.
PMID: 38572811
This study evaluates the sustained antidepressant-like effects and neurogenic potential of a 3-day intranasal co-administration regimen of galanin receptor 2 (GALR2) agonist M1145 and neuropeptide Y Y1 receptor (NPY1R) agonist...
6.
Sanchez-Varo R, Lopez-Salas A, Beltran-Casanueva R, Diaz-Sanchez E, Alvarez-Contino J, Barbancho-Fernandez M, et al.
Behav Brain Funct
. 2024 Mar;
20(1):6.
PMID: 38549164
Background: Spatial memory deficits and reduced neuronal survival contribute to cognitive decline seen in the aging process. Current treatments are limited, emphasizing the need for innovative therapeutic strategies. This research...
7.
Beltran-Casanueva R, Hernandez-Garcia A, de Amo Garcia P, Blanco-Reina E, Serrano-Castro P, Garcia-Casares N, et al.
Front Cell Neurosci
. 2024 Mar;
18:1323986.
PMID: 38425430
Introduction: This study may unveil novel insights into the interactions between neuropeptide Y receptor 1 (NPY1R) and galanin receptor 2 (GALR2), in the dentate gyrus of the dorsal hippocampus, shedding...
8.
Garcia-Casares N, Gonzalez-Gonzalez G, de la Cruz-Cosme C, Garzon-Maldonado F, de Rojas-Leal C, Ariza M, et al.
Rev Endocr Metab Disord
. 2023 May;
24(4):655-672.
PMID: 37231200
Emerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy....
9.
Garcia-Garcia I, Fernandez-Andujar M, Narvaez M, Garcia-Casares N
Obes Rev
. 2023 May;
24(8):e13573.
PMID: 37165483
Midlife obesity and late-life weight loss confer a greater risk for developing dementia and Alzheimer's disease (AD), but the exact mechanisms behind this phenomenon are currently unknown. The answer could...
10.
Diaz-Sanchez E, Lopez-Salas A, Mirchandani-Duque M, Alvarez-Contino J, Sanchez-Perez J, Fuxe K, et al.
Biomed Pharmacother
. 2023 Feb;
161:114433.
PMID: 36848750
Different brain regions' interactions have been implicated in relevant neurological diseases, such as major depressive disorder (MDD), anxiety disorders, age-dependent cognitive decline, Alzheimer's disease (AD) and addiction. We aim to...